[email protected]

– UK, Cambridge – Inivata Limited, a clinical cancer genomics company focused on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment, today announces the appointment of Patrick F. Terry as Non-Executive Board Director. Patrick has co-founded numerous life science organizations and has been at the forefront of applied genomics and personalised medicine for the last 20 years.

In 2000, Patrick and a group of prominent leaders in the fields of genomics, bioinformatics and biotechnology founded Genomic Health, Inc. (NASDAQ:  GHDX), a pioneering personalized medicine company based in California. He has more recently acted as an advisor to multiple life sciences ventures and founded two other applied genetics companies. Patrick has served on the boards of companies in North America and Europe and is currently Chief Commercial Officer at Claritas Genomics.

Patrick has created numerous foundations and philanthropic organisations including the Personalized Medicine Coalition (PMC) and the European Personalized Medicine Association (EPEMED). These organizations were established to advance the understanding of personalised medicine.

He has published dozens of peer-reviewed scientific papers, articles, and book chapters in the field of genetics, personalized medicine, and biomedical research and acts as an editor and advisor to numerous organisations.

Patrick said of his appointment, “I am very excited by the clinical applications of Inivata’s technology and the potential for profound influence on therapeutic effectiveness, care delivery, disease management, and patient outcomes. I believe my experience in shepherding products through development to clinical delivery can help guide the Company’s development and I look forward to working with what is already a very strong board and management team in delivering on the promise of Inivata’s world-class technology.”

Inivata CEO Michael Stocum said, “Patrick is a great person who has seen first-hand the life-changing benefits that personalised medicine and biotechnology can offer.  His direct experience with genetic disease and cancer along with his international business expertise make him the ideal Non-Executive Board Member for Inivata.  We are thrilled to have the advantage he will lend to progressing Inivata’s ctDNA products and business initiatives further.”

About Inivata

Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients.

Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumour DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.

Inivata is based in Cambridge, UK and its scientific founders are leading figures in the ctDNA field: Nitzan Rosenfeld (Cancer Research UK Cambridge Institute, University of Cambridge), Tim Forshew (UCL Cancer Institute, University College London), James Brenton(Cancer Research UK Cambridge Institute, University of Cambridge) and Davina Gale (Cancer Research UK Cambridge Institute, University of Cambridge).

Inivata’s investors and shareholders include Imperial Innovations, Johnson & Johnson Innovation – JJDC, Inc., Cambridge Innovation Capital and Cancer Research Technology.

- DisclaimerNews, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.

Talent4Boards Team

here the original post =>

Comments are closed.